Compare ORBS & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ORBS | CLLS |
|---|---|---|
| Founded | 1966 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 447.0M | 394.4M |
| IPO Year | 2022 | 2014 |
| Metric | ORBS | CLLS |
|---|---|---|
| Price | $0.76 | $0.95 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $4.83 |
| AVG Volume (30 Days) | ★ 14.9M | 93.8K |
| Earning Date | 11-13-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $31,820,779.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $10.70 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.57 | $0.88 |
| 52 Week High | $7.17 | $5.45 |
| Indicator | ORBS | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 37.63 | 21.98 |
| Support Level | $0.74 | N/A |
| Resistance Level | $0.92 | $2.99 |
| Average True Range (ATR) | 0.07 | 0.09 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 17.09 | 15.95 |
Eightco Holdings Inc operates in Forever 8 Inventory Cash Flow Solution. The company is a dynamic technology-focused company committed to driving growth and innovation through strategic acquisitions and management. Forever 8 focuses on purchasing inventory for e-commerce retailers and is part of its Inventory Solution Business. Corrugated Packaging Business manufactured and sold custom packaging for a wide products and through packaging helps customers generate brand awareness and promote brand image. Generate the substantial majority of revenues from inventory financing and inventory management services.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.